Last reviewed · How we verify

NCT06829797: STAR-03

A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting Phase 2 Last updated 17 February 2025
What this trial tests

Phase 2 trial testing Neoadjuvant Therapy(QL1706+SOX Chemotherapy) in Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma in 96 participants. Not yet recruiting.

Timeline
28 February 2025
Primary endpoint
29 February 2028
29 February 2028

Quick facts

Lead sponsorShandong Provincial Hospital
PhasePhase 2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment96
Start date28 February 2025
Primary completion29 February 2028
Estimated completion29 February 2028

Drugs / interventions tested

Conditions studied

Sponsor

Shandong Provincial Hospital

Who can join

Adults 18 to 75, any sex, with Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the efficacy of Iparomlimab and Tuvonralimab (QL1706) in combination with SOX chemotherapy versus chemotherapy alone for the neoadjuvant treatment of locally-progressed gastric/gastroesophageal union adenocarcinomas by evaluating the complete pathologic remission rate (pCR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Currently open trials in the same condition.

Other Shandong Provincial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06829797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing